Genetics (PNPLA3, TM6SF2, HSD17B13) & Family Cirrhosis Screening
How inherited lipid-droplet genes modify MASH progression, when genetic testing helps, and why first-degree relatives of MASLD-cirrhosis patients need elastography screening.
Why does one person live with mild liver fat for 40 years without a trace of scar tissue, while a sibling with the exact same weight and diet develops MASH cirrhosis in their 50s? Genetics supplies a huge piece of that puzzle — led by common variants in PNPLA3, TM6SF2, MBOAT7, and SERPINA1 that trap fat droplets inside liver cells, balanced against naturally protective variants like HSD17B13.
Even without ordering a DNA panel, family history itself is one of the strongest diagnostic tools we have: if your parent, brother, sister, or adult child has cirrhosis from MASLD/MASH, your own odds of silent advanced fibrosis are roughly 12 times higher than average — and AASLD recommends going straight to a liver stiffness scan (FibroScan or MRE) rather than relying on normal liver enzymes.
Prospective family-cohort studies show that parents, full siblings, and adult children of a patient with MASLD-cirrhosis have a ~12-fold higher risk of advanced fibrosis (≥F3) (~15%–18% prevalence vs. ~1%–2% in the general population) — often with completely normal ALT and AST levels.1,2 AASLD explicitly recommends counseling first-degree relatives of MASLD-cirrhosis patients and screening them directly with elastography (VCTE or MRE).1
Major Inherited Variants Shaping MASLD, MASH, and Cirrhosis Risk1,3–6
| Gene & Variant | Biological Mechanism | Clinical Effect on Liver & Lipids | Population Context |
|---|---|---|---|
| PNPLA3 I148M (rs738409 C>G) |
Mutant patatin-like phospholipase accumulates on lipid droplets and traps polyunsaturated triglycerides inside hepatocytes & stellate cells3 | Strongest common genetic driver: ~2×–3.5× higher risk of MASH, bridging fibrosis, cirrhosis, and HCC; multiplicative synergy (>5×–10×) with obesity, T2D, or alcohol1,3 | Present in ~45%–50% of Hispanic/Latino individuals vs. ~23% European and ~15% African ancestry, explaining higher MASH severity even at lower BMI.1,3 |
| TM6SF2 E167K (rs58542926) |
Impairs hepatic VLDL triglyceride export from the endoplasmic reticulum4 | The Lipid–Liver Paradox: lowers circulating LDL cholesterol and triglycerides (reducing heart attack risk) while increasing hepatic fat, MASH fibrosis, and HCC risk4 | Carrier frequency ~7% (European ancestry); explains why some severe MASH patients have “reassuringly low” cholesterol panels. |
| MBOAT7 & GCKR (rs641738 / P446L) |
Altered phosphatidylinositol acyl-chain remodeling (MBOAT7) and unregulated hepatic de novo lipogenesis from glucose (GCKR)3 | Modestly increases steatosis, lobular inflammation, and fibrosis progression, particularly in polygenic risk scores | Common modifiers across European, Asian, and admixed cohorts; intensifies sensitivity to dietary refined carbohydrates/fructose. |
| HSD17B13 LoF (rs72613567 splice) |
Loss-of-function in lipid-droplet retinol/estradiol dehydrogenase reduces inflammatory bioactive lipid signaling5 | Protective Variant: lowers risk of MASH inflammation, F3–F4 fibrosis, and HCC by ~30%–50%, blunting injury even in PNPLA3 I148M carriers5 | Inspired a new class of investigational RNAi therapeutics silencing HSD17B13 to mimic natural genetic resilience. |
| SERPINA1 PI*Z (Glu342Lys / PI*MZ) |
Misfolded alpha-1 antitrypsin polymers accumulate inside hepatocyte ER6 | Heterozygous PI*MZ carrier state acts as a potent “second hit,” doubling to tripling cirrhosis and hepatic decompensation risk in MASLD6 | Carried by ~2%–4% of Northern European descendants; screen with AAT level + PI phenotype. |
Should Every MASLD Patient Order PNPLA3 Testing Today?
- Routine primary care: Not yet required. Both AASLD (2023) and EASL (2024) state that routine population genotyping is not yet recommended because management still hinges on phenotypic fibrosis staging (FIB-4, VCTE, ELF, MRE).1,4
- When academic centers DO consider genetics: Lean MASLD (BMI <25), early-onset or cryptogenic cirrhosis, discordant NITs, strong multi-generation liver disease clustering, or clinical trial enrollment.
What If 23andMe / Consumer DNA Shows PNPLA3 GG?
- Genes are not destiny: Even homozygous PNPLA3 I148M (GG) causes minimal scarring when visceral adiposity, insulin resistance, and alcohol are kept low — and studies show PNPLA3 GG carriers actually experience larger liver-fat drops from weight loss and dietary sugar reduction than non-carriers!3
- Bring the result to your clinician to ensure baseline FIB-4 and elastography staging are completed and alcohol is minimized.